Epiminder Limited

Epiminder Limited develops and commercializes Minder®, an FDA-authorized implantable continuous EEG monitoring (iCEM®) system for long-term brain activity surveillance. The Minder system is designed to address diagnostic and management challenges in drug-resistant epilepsy by enabling continuous neural monitoring over months to years, compared to traditional scalp EEG monitoring limited to days. The implantable device allows patients to maintain normal daily activities while collecting high-quality EEG data, with remote monitoring capabilities to support clinical assessment and treatment planning. Epiminder targets neurologists and epilepsy centers managing patients with drug-resistant epilepsy, representing approximately 1.1 million adults in the US alone. The company emphasizes evidence-based innovation, clinical validation, and collaboration with the global epilepsy care community. Minder represents a significant advancement in seizure detection and neurological monitoring, extending the diagnostic window and providing actionable data to guide therapeutic interventions.